 |
| Analysts find how pre-relocate chemotherapy works with the substitution of microglial cells |
More than 50,000 bone marrow-induced undeveloped cell transplants are performed each year worldwide to treat a variety of conditions, including mental illness. Before the cells are transplanted, patients are given chemotherapy to remove the resistant cells and then prevent the transplanted cells from being rejected by the body. Until now, very few people have been aware of the effects of such treatments on the brain. In another study, scientists at the Institut du Cerveau de Paris (Inserm / CNRS / Sorbonne University) and the Institut Pasteur have considered this question. Using the creature model, they discovered how pre-migratory chemotherapy works with the replacement of microglia, the internal irresponsible cells of the brain.With other protected cells derived from migratory heterogeneous organisms (macrophages). These results are distributed in Nature Medicine.
Many brain infections cause mild demyelination of the focal sensory system with destructive neurological manifestations and the risk of unexpected death (eg leukodestrophy). A standard treatment toward diseases that cause direct hereditary mutations in the underlying bone marrow microorganisms, and the resulting autologous transplant in patients, has recently been established and currently has a large number of these cases. There is a cure for choice.
Medical research has shown that the use of chemotherapy prior to bone marrow transplantation organ transplantation, using a chemotherapy specialist called bisulfan, takes into account the effective engraving and elasticity of genetically modified cells by the body. ۔ In any case, many questions remain, especially about the systems under discussion and the effects of this pre-transfer treatment on patients' minds.
In this regard, the researchers focused on the results of this treatment on different populations of synapses in the creature model. They looked at microglial cells, the brain cells that are needed to maintain a strong brain physiology under normal, neurological conditions. There is a limit to how these cells can regenerate throughout life.
In their work, researchers show that after chemotherapy with bisulfan, microglial cells lose their ability to regenerate completely, and that a considerable number of these cells pass through the senses.
In any case, this cycle will not be harmful to the brain, because after transplantation, the missing cells are immediately replaced by cells (macrophages) attached to the bone marrow. The microglial cells provided by bisulfan chemotherapy leave blank features in brain cells that are filled by macrophages determined by the bone marrow. These macrophages then, at this point, accept the shape and behavior of normal microglia. Future research will be expected to determine whether these macrophages affect each of the characteristics of brain microglial cells.
"Microglial cells play a key role in brain function and in the pathophysiology of many serious neurological infections, both hereditary and complex, such as various sclerosis and Alzheimer's disease. Understanding the fate of these cells after a transition cycle To promote chemotherapy outcomes and new rehabilitation mechanisms for real neurodegenerative diseases, "said Nathalie Cartier, Insom Research Chief at the Neuro Gene Cell Group at the Paris Brain Institute (ICM), and the last co-creator of Focus.
"This study provides an interesting insight into a device that demonstrates how immature microorganisms enter the brain after a determined macrophage bone marrow cell transplant. This better management focal. "The key is to develop new standards for quality and cell therapy for diseases of the sensory system," Pireer stressed. -Marie Lledo, CNRS research chief and top co-creator of the perception and memory unit and final co-creator within the "Qualities, Synapses and Cognition" lab (CNRS / Institut Pasteur).
